Australia based SpeeDx, a developer of innovative molecular diagnostic solutions, has partnered with Roche, a global pioneer in pharmaceuticals and diagnostics, in a non-exclusive agreement to expand global access to SpeeDx infectious disease and antibiotic resistance tests and technology.

SpeeDx offers diagnostics tests for the sexually transmitted infections (STIs) gonorrhea and Mycoplasma genitalium (Mgen).

These STIs are now listed by the Centers for Disease Control and Prevention (CDC) as key threats due to the concerning rise of resistance and the limited available treatment options. Disease management guidelines around the world now focus on the use of resistance identifying diagnostics to help inform treatment.

Under the terms of the agreement, Roche will have non-exclusive access to SpeeDx existing tests and technology - to enable global access and expansion of diagnostic products for the management of antibiotic resistance in STIs, and quickly bring new products to a broader group of patients.